GSK3B and early-onset autosomal dominant Alzheimer disease: Therefore, inhibition of GSK-3β is regarded as a prospective therapeutic strategy for central nervous system (CNS)-related disorders, especially Alzheimer’s disease (AD) (Eldar-Finkelman & Martinez, 2011; Lauretti, Dincer & Praticò, 2020).